The Therapeutic Goods Administration is set to review the safety of an anti-smoking drug following concerns about side effects.
Research published by a Canadian Medical journal found that a PBS listed drug known as Chantix was linked to an increase risk of cardiovascular problems, including sudden heart failure.
But anti-smoking campaigners say the concerns are no reason not to quit.

